All News

malar lupus

Factors Predictive of SLE Flare After HCQ Taper/Discontinuation

MedPage Today

The benefits of hydroxychloroquine in lupus are many, but if you were to withdraw HCQ? A recent study of five Canadian cohorts, suggests that certain baseline variables, including age, race, and steroid use,  were predictive of flare in patients with SLE who tapered or discontinued treatment with hydroxychloroquine.

Read Article
podcast logo

RheumNow Podcast – Steroids, IVIG & the Vaccine (1.15.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. How to handle COVID19 Vaccine issues, IL-6 inhibition in COVID, Comorbidites in RA, IVIG in dermatomyositis, & more...

Read Article
2020 Year Review

2020 Rheumatology Year in Review

Jack Cush, MD

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

Read Article
Jo1.gottrons.jpg

ProDERM Study: IVIG in Dermatomyositis

Jack Cush, MD

The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).

Read Article
lupus.nephritis.immunofluorescence.jpg

Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis

Jack Cush, MD

Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Hydroxychloroquine Shortage During COVID-19

Jack Cush, MD

According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.

Read Article
steroid prednisone lab

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

Jack Cush, MD

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article
FINAL 2020 Podcast Graphic

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

Read Article
Pooled analysis of 16 RCTs in 7044 abatacept treated pts (21,274 PYs exposure) found very low risk of opportunistic infections ranging from OIs 0.17 to 0.21 on ABA and 0.56 on placebo - only 13 TB cases; IR for H zoster was low 1.53/100PY https://t.co/kOWYxEmQLd

Links:

Dr. John Cush RheumNow ( View Tweet)

New QD Clinic—This week’s videos: Clinic Emergencies, Stopping Meds, 3 Issues After COVID Vaccination, My New Clinic COVID Routine, Raynaud's or Not https://t.co/R0zcRq6Sg1

Links:

Dr. John Cush RheumNow ( View Tweet)

2020 Rheumatology Year in Review-- Read our top news items that rheumatologists should recollect and integrate into clinical standards for 2021 and beyond. https://t.co/QisCpdcLEa https://t.co/pZekUvcomE

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Stopping Meds https://t.co/zhtAHLeGqT https://t.co/rFmCch4WJ4

Links:

Dr. John Cush RheumNow ( View Tweet)
Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis--Takeuchi et al has published their extensive experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy. https://t.co/hgMp5GcyFA https://t.co/Xdxg3v3wMm

Links:

Dr. John Cush RheumNow ( View Tweet)
Corticosteroid Use Hikes CV Risks in Rheumatic Patients--It is long known that high-dose steroids may increase the risk of cardiovascular disease (CVD), heart disease, stroke, or other vascular outcomes, but it is unknown what the risk is at lower doses. https://t.co/gkTLP3ceVD https://t.co/HMpvpham1q

Links:

Dr. John Cush RheumNow ( View Tweet)
SOBI announced Kineret is now FDA approved to treat DIRA (defic of IL-1 receptor antagonist), an ultra-rare, autoinflammatory Dz caused by a genetic mutation in the IL1RN gene,. Pts have life-threatening systemic inflammation with skin and bone involvement https://t.co/iccvWYJva9

Links:

Dr. John Cush RheumNow ( View Tweet)

A oatint infected with COVID-19- Yes they should get vaccinated ~90days after infection has resolved.Antibody testing is not needed before you are vaccinated. Evidence suggests that reinfection is uncommon in the 90 days after initial infection. https://t.co/TkcSNx0hF1.

Links:

Dr. John Cush RheumNow ( View Tweet)

Preprint results of the REMAP-CAP trial in the UK shows that IL-6 inhibitors, when given within 24 hrs of ICU entry for COVID-19, lowers mortality rate by 36%. Hosp mortality in 353 TCZ was 28%, 48 sarilumab was 22% in 402 controls was 36%. https://t.co/fkjOz99t0l

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR Convergence 2020 Late Breaking Abstracts available from the ACR "Spotlight" slide give away. 10 slides on COVID, Tyk2 in PsA, FAST febuxostat study, Tofa in AS and novel drugs for SLE and PSS https://t.co/DvcDyusCUR

Links:

Dr. John Cush RheumNow ( View Tweet)

Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis RHAPSODY was a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in 86 patients with recurrent pericarditis Read more: https://t.co/syibq4X7Ps https://t.co/gnxlpOGiHA

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR Guidance on Patient Adherence to Meds--Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease. https://t.co/XwxkFz66fv https://t.co/E6W3H56jps

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×